Business
Virios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate Update
ATLANTA--(BUSINESS WIRE)-- Virios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to
About this update from Dogwood Therapeutics, Inc.
[{"type":"text","content":" ATLANTA--(BUSINESS WIRE)--\nVirios Therapeutics, Inc. (Nasdaq: VIRI), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.\n\n“Our landmark Phase 2b fibromyalgia clinical trial, referred to as FORTRESS, has rapidly progressed and patients are being enrolled at more than 40 clinical trial sites, keeping us on track to announce top line results in mid-2022,” stated Greg Duncan, Chairman and Chief Executive Officer. “There is increasing recognition in the scientific community of the potential role of activated viruses triggering a wide range of conditions, including fibromyalgia, irritable bowel syndrome and fatigue-related disorders. We are exploring the feasibility and timing of executing additional HSV-1 targeted research programs complementary to our fibromyalgia program and expect to provide an update on these plans later this year.”\n\nKey Highlights and Upcoming Milestones\n\n\nEnrollment is ongoing in the FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1) Phase 2b trial;\n\n\n41 clinical trial sites are activated and enrolling patients for the FORTRESS trial;\n\n\nTop line results of the FORTRESS Phase 2b clinical trial are expected in mid-2022;\n\n\nOrally presented gastrointestinal (GI) biopsy study data highlighting the role of active HSV-1 as a potential root cause of chronic GI disorders at Digestive Disease Week 2021;\n\n\nPoster presentation of safety data from the Phase 2a Fibromyalgia Trial at the International Association of the Study of Pain;\n\n\nPoster presentation of the Phase 2a Fibromyalgia Trial data on efficacy analyses of key secondary endpoints at the EULAR European Congress of Rheumatology;\n\n\nPresented at the Needham Healthcare Conference and the Benzinga Global Small Cap Conference;\n\n\nBloomberg News interview in July 2021 with our CEO, Greg Duncan;\n\n\nUpcoming corporate presentations at two investor conferences: SNN Network Summer Virtual Event being held August 17-19, 2021, and H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.\n\n\nSecond Quarter 2021 Financial Results\n\nResearch and development expenses for the second quarter ended ...